Cost-Effectiveness Analysis of a Genetic Screening Program in the Close Relatives of Spanish Patients With Familial Hypercholesterolemia;Análisis coste-efectividad de un programa de cribado genético en familiares directos de pacientes con hipercolesterolemia familiar en España

Revista Espanola de Cardiologia

Volumn 62, Issue 1, 2009, Pages 57-65

  Oliva, Juan ^a,e   López Bastida, Julio ^b,e   Moreno, Santiago G ^c   Mata, Pedro ^d   Alonso, Rodrigo ^d  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^b Servicio de Evaluación   (Spain)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d Instituto Reina Sofía de Investigación Nefrológica   (Spain)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

Cardiovascular event; Cost effectiveness analysis; Economic evaluation; Familial hypercholesterolemia

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR; SIMVASTATIN;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DRUG COST; DRUG EFFICACY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENETIC SCREENING; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SCREENING TEST; SEX DIFFERENCE;

ADULT; AGE FACTORS; COST-BENEFIT ANALYSIS; FAMILY; FEMALE; GENETIC SCREENING; HEALTH CARE COSTS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MODELS, STATISTICAL; SPAIN; YOUNG ADULT;

EID: 59949088744     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(09)70021-1     Document Type: Article

References (29)

1. Goldstein J.L., Hobbs H.H., and Brown M.S. Familial hypercholesterolemia. In: Scriver C.R., Beaudet A.L., Sly W.S., et al. (Eds). The metabolic and molecular basis of inherited disease volume II (2001), McGraw-Hill, New York
2. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 2 (1969) 1380-1382
3. Alonso R., Castillo S., Civeira F., Puzo J., De la Cruz J.J., Pocoví M., et al. [Heterozygous familial hypercholesterolemia in Spain. Description of 819 non related cases]. Med Clin (Barc) 118 (2002) 487-492
4. Hobbs H.H., Brown M.S., and Goldstein J.L. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1 (1992) 445-466
5. Scientific Steering Committee on behalf of the Simon Broome Register Group. The risk of fatal coronary heart disease in familial hypercholesterolemia. BMJ 3030 (1991) 893-896
6. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolemia: implications for clinical management. Atherosclerosis 142 (1999) 105-112
7. WHO Human Genetics Organization. Familial Hypercholesterolemia (FH), Report of a WHO Consultation: WHO/HGN/CONS/98.7. Geneva: World Health Organization; 1998.
8. Marks D., Wonderling D., Thorogood M., Lambert H., Humphries S.E., and Neil H.A. Screening for hypercholesterolemia versus case finding for familial hypercholesterolemia: a systematic review and cost-effectiveness analysis. Health Technol Assess 4 (2000) 1-123
9. Marks D., Wonderling D., Thorogood M., Lambert H., Humphries S.E., and Neil H.A. A cost-effectiveness analysis of different approaches to screening for familial hypercholesterolemia. BMJ 324 (2002) 1303-1308
10. Wonderling D., Umans-Eckenhausen M.A., Marks D., Defesche J.C., Kastelein J.J., and Thorogood M. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin Vasc Med 4 (2004) 97-104
11. Umans-Eckenhausen M.A.W., Defesche J.C., Van Dam M.J., and Kastelein J.P. Long-term compliance to lipid lowering medication after genetic screening for familial hypercholesterolemia. Arch Intern Med 163 (2003) 65-68
12. Tejedor D., Castillo S., Mozas P., Jiménez E., López M., Tejedor M.T., et al. Spanish FH Group. Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 51 (2005) 1137-1144
13. Pocoví M., Civeira F., Alonso R., and Mata P. Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. Semin Vasc Med 1 (2004) 67-74
14. Base de datos de costes sanitarios SOIKOS. Barcelona: SOIKOS; 2004.
15. Conjunto Mínimo Básico de Datos hospitalarios (CMBD). Madrid: Ministerio de Sanidad y Consumo; 2002.
16. Sacristán J.A., Oliva J., Del Llano J., Prieto L., and Pinto J.L. ¿Qué es una tecnología sanitaria eficiente en España?. Gac Sanit 16 (2002) 334-343
17. Luce B.R., Tina Shih Y., and Claxton C. Introduction: Bayesian approach to technology assessment and decision making. Int J Technol Assess Health Care 17 (2001) 1-5
18. Briggs A.H., Goeree R., Blackhouse G., and O'Brien B. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 22 (2002) 290-308
19. Claxton K., Neumann P.J., Araki S., and Weinstein M.C. Bayesian value-of-information analysis: an application to a policy model of Alzheimer's disease. Int J Technol Assess Health Care 17 (2001) 38-55
20. Alonso R., Fernández de Bobadilla J., Méndez I., Lázaro P., Mata N., and Mata P. Coste-efectividad del manejo de la hipercolesterolemia familiar con estrategias de tratamiento preventivo basadas en atorvastatina. Rev Esp Cardiol 61 (2008) 382-393
21. Alonso R., Mata N., Castillo S., Fuentes F., Sáenz P., Muñiz O., et al. Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis (2008) doi:10.1016/j. atherosclerosis.2007.12.024
22. Umans-Eckenhausen M.A., Defesche J.F., Sijbrands E.J., Scheerder R.L., and Kastelein J.J. Review of the first years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 357 (2001) 165-168
23. Damgaard D., Larsen M., Nissen P., Jensen J.M., Jensen H.K., Soerensen V.R., et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 180 (2005) 155-160
24. Smilde T.J., Wissen S., Wollersheim H., Trip M.D., Kastelein J.J., and Stalenhoef A.F. Effect of aggressive versus conventional lipid-lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357 (2001) 577-581
25. International Panel on management of familial hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 173 (2004) 55-68
26. Brown B.G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 (1990) 1289-1298
27. Johannesson M., Jonsson B., Kjekshus J., Olsson A.G., Pedersen T.R., and Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 336 (1997) 332-336
28. Plan Integral de la Cardiopatía Isquémica en España. Madrid: Subdirección General de Estudios Económicos. Ministerio de Sanidad y Consumo; 2003.
29. Oliva J., Lobo F., López-Bastida J., Duque B., and Osuna R. Costes no sanitarios ocasionados por las enfermedades isquémicas del corazón en España. Cuadernos Económicos ICE 67 (2004) 263-298